Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FDA Accepts NDA for Zalunfiban in Prehospital STEMI Treatment

2 October 2026 · By · Wire by Fusion42

Published

2 October 2026

Topic

regulatory

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at hcplive.com →

◆ Verified

Fusion42 · 2 October 2026 · Fusion42 review

The FDA has accepted the New Drug Application (NDA) for Zalunfiban aimed at prehospital treatment of ST-elevation myocardial infarction (STEMI), marking a regulatory step forward for this acute cardiac care intervention.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Your product roadmap now needs to account for new competition if you work in prehospital cardiac treatment—the regulatory gate for Zalunfiban just opened and could change market expectations.

◆ Coverage

1 source · 2 Oct 2026

◆ Related on Wire

◆ Topics

Medtechfdadrug-approvalcardiologyacute-caremedtech